ARA-290 Peptide Protocol Guide - Dosing, Reconstitution & Safety

ARA-290, also called cibinetide, is a small 11-amino-acid peptide built from one piece of the erythropoietin (EPO) molecule. It was engineered to keep EPO's tissue-repair and anti-inflammatory signaling while removing the part that makes red blood cells. In research it is given as a subcutaneous injection from a reconstituted vial.

ARA-290 has more human trial data than many research peptides, especially for sarcoidosis- and diabetes-related nerve symptoms. Development later stalled after Phase 2, with no Phase 3 trial or approval.

ARA-290 dosing is easier to anchor than many peptides because published trials and common research-community protocols use similar ranges. Human studies used daily subcutaneous injections from 1-8 mg, with 4 mg/day appearing most often.

Reconstitution turns the dry powder into a measurable liquid. Concentration is vial size divided by BAC water. Draw volume is target dose divided by concentration. U-100 units are milliliters multiplied by 100.

Example: a 16 mg vial plus 2 mL of BAC water gives 8 mg/mL. A 4 mg dose is then 0.5 mL, which is 50 units on a U-100 syringe. A 10 mg vial plus 2 mL gives 5 mg/mL, so 4 mg becomes 0.8 mL, or 80 units.

This chart summarizes the daily subcutaneous dosing pattern discussed above, including the reported range, cycle length, and route.

In plain terms, EPO does two separate jobs. One job tells bone marrow to make red blood cells. The other job protects and repairs injured tissue and calms inflammation. ARA-290 was designed to trigger only the second job.

It does this by selectively activating the innate repair receptor (IRR), a receptor complex made of the EPO receptor paired with the beta-common receptor (CD131). This is different from the classic EPO receptor pair that drives red-blood-cell production, which is why ARA-290 does not raise hematocrit. ARA-290 also appears to quiet the TRPV1 pain channel on small nerve fibers, which helps explain its effect on neuropathic pain.

ARA-290 was generally well tolerated in short human trials, but the available safety data is limited to small groups and relatively brief study windows. These cautions are conservative research context, not a medical screening tool.

Across the Phase 2 trials, ARA-290 was generally well tolerated. Reported effects were mostly mild and short-lived, and no serious drug-related safety problems were flagged in the published studies.

The important caveat is scale. Combined trial enrollment was under about 200 people, and treatment lasted weeks, not months. That means long-term safety at any dose is simply not characterized.

The trial timelines are short and specific. Most studies ran daily subcutaneous ARA-290 for 28 days. In the Phase 2b sarcoidosis trial, measurable nerve-fiber regrowth on corneal imaging and pain improvement were seen within that 28-day window. In the diabetes trial, some benefits persisted through a 28-day follow-up after dosing stopped.

For research planning, the main things to track are symptom scores, injection-site reactions, and any unexpected side effects. Because the compound is EPO-derived, some researchers also note red-blood-cell parameters as a precaution, even though trials showed no erythropoietic effect.

ARA-290 has more human evidence than many peptides covered in research guides, but the evidence base is still small and stops at Phase 2. All the main trials were run or sponsored by the developer, Araim Pharmaceuticals.

The main limitation is the missing next step: no Phase 3 trial was completed, and the developer reportedly wound down operations with no active US IND as of 2026. That leaves promising Phase 2 signals for nerve pain and regeneration, but no completed approval path. Popular claims about broad anti-aging or bodybuilding benefits are not supported by these trials.

As of July 2026, ARA-290 (cibinetide) is not FDA-approved for any indication. It received FDA Orphan Drug and Fast Track designations for neuropathic pain in sarcoidosis, plus EU orphan designation, but those are development incentives, not approvals. No NDA or BLA was ever submitted.

Multiple industry and reference sources report that the developer, Araim Pharmaceuticals, has wound down, with no active US IND and no Phase 3 program. Reporting attributes the stall to commercial and organizational factors rather than a specific safety problem. ARA-290 sold as a research peptide is a research-use-only product, not an approved medicine, and is not the same as a licensed formulation.

ARA-290 is often compared to BPC-157 because both are discussed for repair. They are quite different. BPC-157 is a broad soft-tissue recovery peptide with mostly animal evidence. ARA-290 is a targeted innate-repair-receptor agonist with actual human Phase 2 data, but focused on nerve and inflammatory endpoints rather than general tissue repair.